Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0025202 (melanoma)
 69,561 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The ability of groups of pathologists to classify and stage malignant melanoma varies with their familiarity with the new nomenclature proposed for that process. Primary lesions of malignant melanoma from 79 patients were independently examined and classified by community pathologists, university pathologists, and a referee pathologist all without access to each others diagnoses. The diagnoses of these groups were compared for agreement in variety of melanoma as well as depth of dermal penetration (stage or level). Greatest success (agreement with the referee) of both the community pathologists and the university pathologists was achieved when assessment of level of invasion (+/- 1) of the referee was compared (community pathologists = 94% +/- 12% agreement, university pathologists = 99% +/- 2% agreement). Our survey demonstrates that only a relatively small number of community pathologists (23%) employ the new nomenclature, but they do so with a facility equal to that of the university pathologists. Based upon this study and our continuing experiences, we recommend the review of all primary lesions of malignant melanoma by a pathologist or group experienced in the diagnosis and microscopic staging of the disease.
Cancer 1977 Dec
PMID:Comparison of the classification by microscopic level (stage) of malignant melanoma by three independent groups of pathologists. 58 69

Pigmented lesions of the vagina are very rare. A benign blue nevus of the vagina in a 73-year-old woman, diagnosed clinically as malignant melanoma, is presented. Although 15 cases of blue nevi of the uterine cervix have been reported, this is the first case of blue nevus located exclusively in the vagina.
Cancer 1977 Dec
PMID:Benign blue nevus of the vagina. 58 75

Ninety-four patients with malignant melanoma and 96 healthy controls were tested for lymphocyte proliferative capacity in a microblastogenesis assay. Each lymphocyte sample was assayed for incorporation of (3H)thymidine after stimulation with PHA, PWM, Con A (two doses), PPD, and allogeneic lymphocytes (MLC). MLC was the only assay that revealed a substantial and significant difference between the melanoma patients and controls. Almost all assays showed lower values in patients with more advanced disease. However, it was not possible to accurately predict clinical outcome from data obtained from in vitro immunocompetence tests. These results indicate the relatively limited clinical usefulness of assays of lymphocyte proliferative capacity in melanoma patients.
Int J Cancer 1977 Dec 15
PMID:In vitro assessment of immunocompetence in patients with malignant melanoma. 59 Nov 27

Tumorigenicity is reversibly suppressed in mouse melanoma cells grown with 5-bromodeoxyuridine (BrdU). The nontumorigenic cells are immunogenic, and preinjection of these cells can protect mice against tumors inevitably formed when the parental, untreated melanoma cells are inoculated into inbred strain C57BL/6. A mixture of highly immunogenic clone, C(3)471, with malignant cells is also nontumorigenic. These effects are related to the host immune response since they occur only in immunocompetent mice. BrdU also reversibly suppresses functions related to pigment formation and plasminogen activation. These effects require incorporation of BrdU into DNA, emphasizing the value of the thymidine analog, BrdU as a tool to relate normal regulation of gene activity to perturbations of this regulation which produce malignant cells. This research can facilitate basic understanding of the malignant state and its relationship to host response as well as a method for immunizing melanoma patients after surgery to prevent tumor recurrence.
Am J Pathol 1977 Dec
PMID:Reversible suppression of malignancy and differentiation of melanoma cells. 59 22

Women who had used oral contraceptives, particularly long-term users, were found to have higher rates of malignant melanoma and of a past history of skin cancer than those who had never used oral contraceptives. This excess was confined to lesions of the lower limb. The association between oral contraceptive use and melanoma was noted in 3 separate sets of data, although it was statistically significant only in one. The possibility that this relationship is indirect because, for example, oral contraceptive users are more likely than never-users to be exposed to sunlight and thus to develop malignant melanoma, cannot be excluded.
Br J Cancer 1977 Dec
PMID:Malignant melanoma and oral contraceptive use among women in California. 59 78

The fate of over 1,500 patients treated for malignant melanoma in Queensland, Australia, between 1963 and 1969 has been followed by the Queensland Melanoma Project (QMP). Aspects which have been studied and reported include yearly incidence (16 per 100,000), sex incidence (females 55%, males 45%), size of melanomas (73% less than 2.0 cm), prognosis related to sex, site and histological features, multiple primary cutaneous melanomas (more than 1 in 4.8% of patients), hereditary and immunological aspects and value of frozen section diagnosis in management. Continued education of the public and medical practitioners is essential to insure early diagnosis and appropriate management of patients with melanoma.
Int J Dermatol 1977 Dec
PMID:The Queensland melanoma project. 59 56

We tried to confirm the anamnestical data of patients with malignant melanoma with the aid of private photos. The statement of the patients that a "birth-mark" was present before the development of the malignant melanoma could nearly always be corroborated by the photographs. The patients' statements that the tumor had developed in uninvolved epidermis in a relatively short time proved to be correct in many cases. In some cases, however, the "birth-marks" could be detected on the photographs at a time, when these marks were not yet recognized by the patients. According to the statement of the patients and the results of the pictures, lentigo maligna-melanoma, superficial spreading melanoma, and nodular melanoma can originate from a pre-existing pigmented spot or can develop in a relatively short time in uninvolved epidermis. In most cases of lentigo maligna-melanoma a long history and a slow tumor growth is stated. Generally the development of nodular melanoma is extremely short. In cases of superficial spreading melanoma the time of tumor growth was reported to be a few month or up to one or two years. In some cases, however, a much slower development of the tumor could be detected with the aid of the photographs.
Hautarzt 1977 Dec
PMID:[Development of malignant melanomas on preexisting pigmentary lesions. Control of anamnestic data based on patients private photographic series]. 59 24

Nine patients with advanced cancer who were receiving the methanol extraction residue of BCG (MER-BCG) intradermally or intratumorally underwent biopsies from the injected sites or from locally enlarged lymph nodes. Most preparations showed a chronic granulomatous reaction consisting of lymphocytes, histiocytes, and epithelioid cells as well as either Langhans's or foreignbody type giant cells, or both. The degree of granuloma formation and giant cell infiltration varied. In only one case did the reactions consist merely of chronic lymphocytic and histiocytic inflammation with no granuloma formation. Examination of melanoma nodules injected with MER showed, in addition to granulomas, large numbers of giant cells penetrating the tumour.
J Clin Pathol 1977 Dec
PMID:Granuloma formation in patients after injection of methanol extraction residue (MER-GCG). 60 61

From the time of its inception in 1955, the Drug Development Program of the National Cancer Institute has relied primarily on transplanted rodent tumor systems in vivo for the evaluation and selection of potential antitumor agents. Although greater emphasis has been placed in recent years on rationally designed drugs, the major effort throughout the history of the program has involved the empirical screening of a wide variety of chemical structures and natural products of varying sources. The initial screening spectrum consisted of three mouse tumors, Sarcoma 180, Carcinoma 755 and Leukemia 1210, based on the retrospective analysis presented in the GELLHORN-HIRSCHBERG Report. As a result of further expermental studies and analyses, the screens changed successively to (1) L1210 plus a spectrum of mouse, rat and hamster tumors, (2) L1210 plus the rat tumor, WALKER 256, (3) L1210, plus P388 for natural products and B16 melanoma and LEWIS lung carcinoma for special studies, and finally (4) P388 as a pre-screen followed by a panel of transplanted tumors and xenografts representing the major tumor sites. The rationale underlying each of the successive changes, and results obtained with each approach, will be discussed.
Jpn J Antibiot 1977 Dec
PMID:Antitumor screening procedures of the National Cancer Institute. 61 10

Cancer registration, introduced in New Zealand in 1948, evolved from a clinically oriented to a population-based collection scheme. The registry, located within the National Health Statistics Centre, can draw on a wide range of other health data reported to that office. New Zealand has a population of 3 million, 8% of whom are Maoris. Findings indicated that cancer is the second leading cause of death and that Maori women have a much higher overall cancer death toll than other New Zealand women. Significantly higher incidence rates for cancers of the stomach, pancreas, lung, thyroid gland, and uterus and lower rates for cancer of the large bowel and melanoma of the skin were found in Maoris.
Natl Cancer Inst Monogr 1977 Dec
PMID:Cancer registry in New Zealand. 61 45


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>